NZ630011A - Method for treating gynecological diseases - Google Patents
Method for treating gynecological diseasesInfo
- Publication number
- NZ630011A NZ630011A NZ630011A NZ63001113A NZ630011A NZ 630011 A NZ630011 A NZ 630011A NZ 630011 A NZ630011 A NZ 630011A NZ 63001113 A NZ63001113 A NZ 63001113A NZ 630011 A NZ630011 A NZ 630011A
- Authority
- NZ
- New Zealand
- Prior art keywords
- progesterone receptor
- gynecological diseases
- treating gynecological
- pharmaceutical composition
- combination
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000002379 progesterone receptor modulator Substances 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229940095745 sex hormone and modulator of the genital system progesterone receptor modulator Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 229960000499 ulipristal acetate Drugs 0.000 abstract 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614785P | 2012-03-23 | 2012-03-23 | |
| EP12160956.4A EP2641602A1 (en) | 2012-03-23 | 2012-03-23 | Method for treating gynecological diseases |
| PCT/IB2013/052274 WO2013140372A1 (en) | 2012-03-23 | 2013-03-22 | Method for treating gynecological diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ630011A true NZ630011A (en) | 2016-12-23 |
Family
ID=45976689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ630011A NZ630011A (en) | 2012-03-23 | 2013-03-22 | Method for treating gynecological diseases |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10441534B2 (enExample) |
| EP (3) | EP2641602A1 (enExample) |
| JP (2) | JP2015514700A (enExample) |
| KR (1) | KR20140138824A (enExample) |
| CN (1) | CN104203246A (enExample) |
| AU (1) | AU2013236960B2 (enExample) |
| CA (1) | CA2864073A1 (enExample) |
| CO (1) | CO7111317A2 (enExample) |
| EA (1) | EA031488B1 (enExample) |
| GE (1) | GEP201706696B (enExample) |
| HK (1) | HK1199827A1 (enExample) |
| MX (1) | MX369520B (enExample) |
| MY (1) | MY172530A (enExample) |
| NZ (1) | NZ630011A (enExample) |
| SG (1) | SG11201404921QA (enExample) |
| TW (2) | TW201832767A (enExample) |
| WO (1) | WO2013140372A1 (enExample) |
| ZA (1) | ZA201407575B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017112909A1 (en) | 2015-12-23 | 2017-06-29 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| JP6906525B2 (ja) | 2015-12-23 | 2021-07-21 | オリック ファーマシューティカルズ，インク． | グルココルチコイド受容体の阻害剤 |
| US11110103B2 (en) | 2015-12-23 | 2021-09-07 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| WO2017165707A1 (en) * | 2016-03-24 | 2017-09-28 | Juniper Pharmaceuticals, Inc. | Vaginal administration of agents for treating and preventing pain associated with gynecological medical procedures |
| PT3523315T (pt) | 2016-10-07 | 2021-04-29 | Oric Pharmaceuticals Inc | Inibidor de recetor de glucocorticoide |
| US20240122885A1 (en) * | 2021-02-12 | 2024-04-18 | The Regents Of The University Of California | Endometriosis-Related Methods and Compositions |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3545439A (en) | 1968-01-04 | 1970-12-08 | Upjohn Co | Medicated devices and methods |
| US3920805A (en) | 1971-12-09 | 1975-11-18 | Upjohn Co | Pharmaceutical devices and method |
| US4155991A (en) | 1974-10-18 | 1979-05-22 | Schering Aktiengesellschaft | Vaginal ring |
| IL48277A (en) | 1974-10-18 | 1978-03-10 | Schering Ag | Vaginal ring |
| US3995634A (en) | 1975-12-02 | 1976-12-07 | The Procter & Gamble Company | Vaginal cavity dispensing means and method |
| US3995633A (en) | 1975-12-02 | 1976-12-07 | The Procter & Gamble Company | Vaginal Medicament dispensing device |
| US3991760A (en) | 1975-12-02 | 1976-11-16 | The Procter & Gamble Company | Vaginal medicament dispensing means |
| US4286587A (en) | 1978-10-11 | 1981-09-01 | Alza Corporation | Vaginal drug delivery system made from polymer |
| US4292965A (en) | 1978-12-29 | 1981-10-06 | The Population Council, Inc. | Intravaginal ring |
| US4250611A (en) | 1979-04-19 | 1981-02-17 | Alza Corporation | Process for making drug delivery device with reservoir |
| EP0180264A1 (en) | 1984-10-12 | 1986-05-07 | Akzo N.V. | Release system for two or more active substances |
| NL8500470A (nl) | 1985-02-19 | 1986-09-16 | Achel Homesteel Pvba | Intravaginaal orgaan. |
| US4954490A (en) | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
| FI95768C (fi) | 1993-06-17 | 1996-03-25 | Leiras Oy | Emättimensisäinen antosysteemi |
| US5929262A (en) | 1995-03-30 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates |
| US5972372A (en) | 1996-07-31 | 1999-10-26 | The Population Council, Inc. | Intravaginal rings with insertable drug-containing core |
| ES2212912B1 (es) | 2003-01-22 | 2005-10-01 | Crystal Pharma, S.A. | Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona. |
| AU2004217988C1 (en) | 2003-02-28 | 2010-06-03 | Southwest Foundation For Biomedical Research | Method for preparing 17 alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates |
| JP5017109B2 (ja) | 2004-07-09 | 2012-09-05 | ザ・ポピュレイション・カウンシル，インコーポレイテッド | プロゲステロン受容体モジュレーターを含有する徐放性組成物 |
| SI2148681T1 (sl) * | 2007-04-20 | 2016-07-29 | Preglem S.A. | Selektivni modulatorji progesterona v zdravljenju maternične krvavitve |
| US8299050B2 (en) * | 2008-01-29 | 2012-10-30 | Laboratoire Hra-Pharma | Method for treating uterine fibroids |
| ES2648640T3 (es) * | 2008-02-04 | 2018-01-04 | Ferring B.V. | Anillos intravaginales monolíticos que comprenden progesterona y métodos de fabricación y usos de los mismos |
-
2012
- 2012-03-23 EP EP12160956.4A patent/EP2641602A1/en not_active Withdrawn
-
2013
- 2013-03-22 WO PCT/IB2013/052274 patent/WO2013140372A1/en not_active Ceased
- 2013-03-22 JP JP2015501044A patent/JP2015514700A/ja active Pending
- 2013-03-22 CA CA2864073A patent/CA2864073A1/en not_active Abandoned
- 2013-03-22 TW TW107104368A patent/TW201832767A/zh unknown
- 2013-03-22 HK HK15100309.9A patent/HK1199827A1/xx unknown
- 2013-03-22 AU AU2013236960A patent/AU2013236960B2/en not_active Ceased
- 2013-03-22 SG SG11201404921QA patent/SG11201404921QA/en unknown
- 2013-03-22 CN CN201380014168.1A patent/CN104203246A/zh active Pending
- 2013-03-22 GE GEAP201313608A patent/GEP201706696B/en unknown
- 2013-03-22 MY MYPI2014002228A patent/MY172530A/en unknown
- 2013-03-22 NZ NZ630011A patent/NZ630011A/en not_active IP Right Cessation
- 2013-03-22 TW TW102110291A patent/TW201400121A/zh unknown
- 2013-03-22 US US14/386,726 patent/US10441534B2/en not_active Expired - Fee Related
- 2013-03-22 EP EP17192417.8A patent/EP3363500A1/en not_active Withdrawn
- 2013-03-22 KR KR1020147027575A patent/KR20140138824A/ko not_active Ceased
- 2013-03-22 MX MX2014011487A patent/MX369520B/es active IP Right Grant
- 2013-03-22 EP EP13721095.1A patent/EP2827873A1/en not_active Ceased
- 2013-03-22 EA EA201491614A patent/EA031488B1/ru not_active IP Right Cessation
-
2014
- 2014-10-17 ZA ZA2014/07575A patent/ZA201407575B/en unknown
- 2014-10-20 CO CO14231832A patent/CO7111317A2/es unknown
-
2018
- 2018-02-13 JP JP2018023604A patent/JP2018109025A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA201491614A1 (ru) | 2015-01-30 |
| WO2013140372A1 (en) | 2013-09-26 |
| TW201400121A (zh) | 2014-01-01 |
| TW201832767A (zh) | 2018-09-16 |
| AU2013236960A1 (en) | 2014-09-25 |
| EP2827873A1 (en) | 2015-01-28 |
| SG11201404921QA (en) | 2014-10-30 |
| CA2864073A1 (en) | 2013-09-26 |
| EP3363500A1 (en) | 2018-08-22 |
| MY172530A (en) | 2019-11-29 |
| JP2015514700A (ja) | 2015-05-21 |
| US20150038476A1 (en) | 2015-02-05 |
| US10441534B2 (en) | 2019-10-15 |
| CN104203246A (zh) | 2014-12-10 |
| HK1199827A1 (en) | 2015-07-24 |
| GEP201706696B (en) | 2017-07-10 |
| JP2018109025A (ja) | 2018-07-12 |
| MX369520B (es) | 2019-11-11 |
| ZA201407575B (en) | 2015-12-23 |
| CO7111317A2 (es) | 2014-11-10 |
| EA031488B1 (ru) | 2019-01-31 |
| MX2014011487A (es) | 2015-01-12 |
| AU2013236960B2 (en) | 2017-11-23 |
| KR20140138824A (ko) | 2014-12-04 |
| EP2641602A1 (en) | 2013-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12014502516B1 (en) | Formulations and methods for vaginal delivery of antiprogestins | |
| PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015501600A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| JOP20130236B1 (ar) | تركيبات صيدلانية تشتمل على مثبط b-raf ومثبط egfr ومثبط اختياري لــpi3k alpha | |
| MX354210B (es) | Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas. | |
| MY172530A (en) | Method for treating gynecological diseases | |
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| CU20120175A7 (es) | Compuestos derivados de 6,7-dihidro-5h-benzo[7]anulenos | |
| MX2012014521A (es) | Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion. | |
| MX361349B (es) | Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas. | |
| TN2015000007A1 (en) | 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments | |
| PH12012501389A1 (en) | Hedgehog inhibitors | |
| MX2016002408A (es) | Metodos para el tratamiento de trastornos oticos pediatricos. | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| HK1215391A1 (zh) | 使用胎盘细胞外基质治疗口腔病变 | |
| EA201390417A1 (ru) | Антидиабетические твердые фармацевтические композиции | |
| MX2015005993A (es) | Composiciones y metodos para el tratamiento de displasia ectodermica. | |
| CL2015003014A1 (es) | Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas. | |
| WO2011049954A3 (en) | Compositions comprising wnt modulators or neurotoxins for the treatment of otic disorders | |
| EP2957569A4 (en) | (ARGO) N-ANGIOTENSIN (1-7) PEPTIDE AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ILLNESSES | |
| MX372644B (es) | Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro. | |
| MX2017000399A (es) | Tableta dispersable de misoprostol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 22 MAR 2020 BY DENNEMEYER + CO. Effective date: 20170413 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2021 BY DENNEMEYER + CO. Effective date: 20200219 |
|
| LAPS | Patent lapsed |